scholarly journals Persistence of Zika Virus in Body Fluids — Final Report

2018 ◽  
Vol 379 (13) ◽  
pp. 1234-1243 ◽  
Author(s):  
Gabriela Paz-Bailey ◽  
Eli S. Rosenberg ◽  
Kate Doyle ◽  
Jorge Munoz-Jordan ◽  
Gilberto A. Santiago ◽  
...  
Keyword(s):  
2017 ◽  
Author(s):  
Charles Chiu ◽  
Jerome Bouquet ◽  
Tony Li ◽  
Shigeo Yagi ◽  
Claudia Sanchez San Martin ◽  
...  

ABSTRACTHuman infections by Zika virus (ZIKV), a mosquito-borne flavivirus, are associated with a current widespread outbreak in the Americas, and have been associated with neurological complications and adverse fetal outcomes such as microcephaly in pregnant women. A suitable non-human primate model is urgently needed. To evaluate ZIKV infectivity, pathogenesis, and persistence, we inoculated 4 marmosets with ZIKV and followed them by clinical monitoring and serial sampling of body fluids for up to 11 weeks. We found that marmosets experimentally infected with ZIKV reproduced key features of the human disease, including (1) asymptomatic infection, (2) brief period of detectable virus in serum (<1 week), (3) detection in other body fluids (urine, saliva, semen, and stool) for at least 2 weeks following acute infection, and (4) persistence in lymph nodes, but not other tissues, at 1 month post-infection. ZIKV-positive saliva and serum samples, but not urine, were found to be infectious in cell culture. By day 6 post-inoculation, most marmosets exhibited detectable neutralizing antibody responses concurrent with activation of NK cell and B cell subsets and an increase in circulating cytokines associated with type II interferon signaling, Transcriptome profiling revealed enrichment of immune responses to active viral infection, with up-regulation of both type I and II interferon signaling pathways, anduncovered potential host biomarkers. These results suggest that a New World monkey model of acute ZIKV infection mimics the human disease, and is likely to be useful for testing of drug and vaccine candidates.


2018 ◽  
Vol 18 (3) ◽  
pp. 328-336 ◽  
Author(s):  
Thalia Velho Barreto de Araújo ◽  
Ricardo Arraes de Alencar Ximenes ◽  
Demócrito de Barros Miranda-Filho ◽  
Wayner Vieira Souza ◽  
Ulisses Ramos Montarroyos ◽  
...  

2019 ◽  
Vol 100 (2) ◽  
pp. 427-433 ◽  
Author(s):  
Rodion Gorchakov ◽  
Rebecca M. Berry ◽  
Shital M. Patel ◽  
Hana M. El Sahly ◽  
Shannon E. Ronca ◽  
...  
Keyword(s):  

2018 ◽  
Vol 24 (10) ◽  
pp. 1111-1112 ◽  
Author(s):  
M. Giovanetti ◽  
J. Goes de Jesus ◽  
M. Lima de Maia ◽  
J.X. Junior ◽  
M.F. Castro Amarante ◽  
...  

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S991-S992
Author(s):  
Paola Lichtenberger ◽  
Mike Ricciardi ◽  
Dalhila Solorzano ◽  
Patricia Raccamarich ◽  
Ana R Leda ◽  
...  

Abstract Background A laboratory worker suffered an accidental needle stick resulting in infection with the Ugandan strain (MR766) of Zika virus (ZIKV), a strain that has rarely been studied in humans. We report the clinical presentation and outcomes, molecular and serological diagnostic results, and immunological response. A 34-year-old Brazilian-born female laboratory researcher, presented with malaise, skin rash, myalgia and joint pain 10 days after an accidental needle stick while inoculating a mouse with ZIKV-MR766. On physical examination she had bilateral maculopapular rash on the cheeks, and tender effusions at the metacarpal and proximal interphalangeal joints and ankles. Symptoms and signs resolved within 3 weeks. ZIKV infection was confirmed by Nucleic Acid Amplification Test (Lab Corp®) in urine. Serological testing using the ZIKV IgM ELISA test from Lab Corp®, and a confirmatory plaque reduction neutralization test (PRNT) in accordance with the Centers for Disease Control and Prevention (CDC), results were negative. Methods Whole blood, plasma, urine, saliva, and a vaginal swab were collected from day (D) 14 post exposure (PE) to D104 PE. A novel, antibody competition-based ZIKV diagnostic test (highly specific for ZIKV antibodies) was performed in serum, and detection of ZIKV-MR766 genomic RNA was performed in all body fluids longitudinally. Results Antibody response revealed broad IgM response to both ZIKV-Paraiba (strain from the 2015 outbreak) and ZIKV-MR766 during the acute phase of the infection, suggesting cross-reactivity. There was no cross-reactivity against dengue or yellow fever viruses. An IgG response was detected against both ZIKV strains and increased until D104 PE. ZIKV RNA was detected in whole blood, saliva, urine, and the vaginal swab at D14 PE. At D20 PE, virus was only detectable in whole blood at a value of less than 37 copies per mL. At D23 PE, there was no detectable virus. (figure). Conclusion This case highlights the potential for ZIKV occupational exposure. Findings may be useful for the development of diagnostic tests against ZIKV as we were able to accurately determine time of exposure, presence of virus in body fluids, development of symptoms, and antibody responses after a well-documented infection. Disclosures All authors: No reported disclosures.


Sign in / Sign up

Export Citation Format

Share Document